Announced
Completed
Financials
Tags
Acquisition
biotech
Single Bidder
Canada
Friendly
Biotechnology
Cross Border
Majority
Public
Completed
Synopsis
GSK, a global healthcare company, completed the acquisition of BELLUS Health, a biopharmaceutical company, for $2bn. “This acquisition recognises the value of our highly selective P2X3 antagonist camlipixant and validates the hard work and dedication of all the BELLUS employees in advancing camlipixant to date. As a leader in respiratory research for over five decades, GSK shares our commitment to bettering the lives of individuals suffering from a persistent cough and is the ideal Company to rapidly bring camlipixant to the millions suffering from refractory chronic cough around the world,” Roberto Bellini, BELLUS CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.